Cargando…

Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)

AIM: The aim of this study was to describe the testing rate and frequency of molecular alterations observed in the Lung Cancer Biomarker Testing Registry (LungPath). METHODS: A descriptive study of NSCLC biomarker determinations collected from March 2018 to January 2019, from 38 Spanish hospitals, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salas, Clara, Martín-López, Javier, Martínez-Pozo, Antonio, Hernández-Iglesias, Teresa, Carcedo, David, Ruiz de Alda, Lucia, García, J Francisco, Rojo, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862081/ https://www.ncbi.nlm.nih.gov/pubmed/33722840 http://dx.doi.org/10.1136/jclinpath-2020-207280

Ejemplares similares

Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)
por: Martín-López, Javier, et al.
Publicado: (2023)

Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain
por: Rojo, Federico, et al.
Publicado: (2022)

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
por: Isla, Dolores, et al.
Publicado: (2022)

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario
por: Nadal, Ernest, et al.
Publicado: (2021)

Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
por: Isla, Dolores, et al.
Publicado: (2023)

La pandemia de la COVID-19 desde la SEAP
por: Rodríguez-Peralto, José Luis
Publicado: (2020)

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)
por: Palacios, J., et al.
Publicado: (2019)

Lung cancer biomarker testing: perspective from Europe
por: Thunnissen, Erik, et al.
Publicado: (2020)

Lung cancer biomarker tests: the history and perspective in Japan
por: Motoi, Noriko, et al.
Publicado: (2020)

Assessment of Biomarker Testing for Lung Cancer Screening Eligibility
por: Larose, Tricia L., et al.
Publicado: (2020)

Biomarker Testing for People With Advanced Lung Cancer in England
por: Adizie, Jana B., et al.
Publicado: (2021)

Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP): An Overview and Lessons Learned
por: Barkume, Caitlin, et al.
Publicado: (2018)

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
por: Garrido, P., et al.
Publicado: (2019)

Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)
por: Guo, Shicheng, et al.
Publicado: (2015)

The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis
por: Fang, Rui, et al.
Publicado: (2018)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
por: Liu, Stephen V., et al.
Publicado: (2023)

MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
por: Liao, Jipei, et al.
Publicado: (2020)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Šutić, Maja, et al.
Publicado: (2021)

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective
por: Brega, Elisa, et al.
Publicado: (2014)

Biomarker testing of cytology specimens in personalized medicine for lung cancer patients
por: Kim, Hyojin, et al.
Publicado: (2022)

Developing and Pilot Testing a Spanish Translation of CollaboRATE for Use in the United States
por: Forcino, Rachel C., et al.
Publicado: (2016)

Patterns of active and passive smoking, and associated factors, in the South-east Anatolian Project (SEAP) region in Turkey
por: Bozkurt, Ali I, et al.
Publicado: (2006)

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
por: Hess, Lisa M., et al.
Publicado: (2022)

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers
por: Venetis, Konstantinos, et al.
Publicado: (2020)

Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys
por: Keppens, Cleo, et al.
Publicado: (2020)

Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH
por: Garrido, P., et al.
Publicado: (2017)

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)
por: Quinton, Cindy, et al.
Publicado: (2011)

Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC
por: Vuong, Diem, et al.
Publicado: (2021)

Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
por: Zarinshenas, Reza, et al.
Publicado: (2023)

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
por: Colomer, R., et al.
Publicado: (2017)

Biomarker Testing for Actionable Alterations in NSCLC—Perspectives from US-Based Academic and Community Oncologists: A Podcast
por: Iams, Wade T., et al.
Publicado: (2023)

Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
por: Topchu, Iuliia, et al.
Publicado: (2021)

Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II(+) detection rates
por: Rozemeijer, Kirsten, et al.
Publicado: (2015)

Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT(®)-Lung Test
por: Macdonald, Isabel K., et al.
Publicado: (2012)

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
por: Grigg, Claud, et al.
Publicado: (2016)

608. Systematic Fungal Biomarker Testing in Lung Transplant Recipients : Retrospective Analysis to Optimize Their Use
por: Boutin, Catherine-Audrey, et al.
Publicado: (2023)

Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
por: Herbst, Roy S., et al.
Publicado: (2021)

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico
por: Greenbaum, Alissa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t26092h4tjenr8fvclnefbb1eg